Why Gabor-Granger Analysis Matters in MedTech
In MedTech, pricing decisions must balance value, affordability, and adoption. Stakeholders do not just interpret price — they respond to it. As prices increase, acceptance does not decline in a linear or predictable way. Understanding where demand starts to drop is critical to defining a viable pricing strategy.
Gabor-Granger analysis matters because it answers a key commercial question: how does demand change as price changes?
By measuring willingness-to-pay across multiple price points, it provides a clearer view of: Where pricing begins to limit adoption and how sensitive different stakeholders are to price.
This is particularly valuable in medical device pricing research, where pricing decisions directly impact both market access and revenue potential.
How price signals value and risk
Understanding when pricing reinforces credibility versus raising concerns about quality or cost.
Where pricing may restrict adoption
Identifying thresholds where stakeholders begin to reject the product on price alone.
Where opportunities exist to differentiate and reposition
Highlighting gaps in the market and areas where new or existing products can stand out.
This creates a strong foundation for further medical device pricing analysis, but not a final answer.